Quick-Mitome, developed by an international consortium of mitochondrial disease specialists, is available for non-commercial, non-clinical research.

This new method, typically used in adult patients, may spare patients from having to undergo open heart surgery.

Researchers from Children’s Hospital of Philadelphia (CHOP) and Johns Hopkins University School of Medicine studied how high levels of substance and polysubstance use are associated with sexual practices, and partner characteristics that can reinforce risk for HIV acquisition or transmission among Black and Latinx sexual youth as well as gender minority youth. 

Children’s Hospital of Philadelphia is proud to announce the initial results of an experimental gene therapy treatment of a patient with hereditary hearing loss in the United States. Findings to date indicate that the treatment was successful.

Vaccination associated with moderate protection in large, diverse cohort.

Data from this method could be used to discover how cancers are able to evade therapy and provide better insight into underlying tumor mechanisms.

Medically indicated preterm births, like cesarean sections and induced births, can be a sign of other negative health issues affecting patients at neighborhood levels.

The study also found that increased fat and protein intake may improve muscle strength and quality of life in patients with mitochondrial disease.

The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease  in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 

Identifying “backbones” that link complexes can help maximize CAR therapy across different variants and tumor types.